Effect of Polygenic Risk Modifiers on Decisions of BRCA1/2 Mutation Carriers at Risk for Prostate Cancer
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Eligibility
- Age range
- 45–70 years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: * Documentation of Disease o Patients must not have prostate cancer * Age between 45 - 70; * Assigned male sex at birth * Completed full sequence or targeted genetic testing with a result confirmed in a clinically approved laboratory showing a BRCA1/2 likely pathogenic or pathogenic variant identified, or clinician note documents a BRCA1/2 likely pathogenic or pathogenic variant * English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestabl…
Interventions
- Geneticcheek (buccal) swab
swab sample in person or at home with a mailed test kit and will fill out a survey
- OtherAssessments
about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.
- Otheroptional collection of blood
for research testing
Location
- Memorial Sloan Kettering Cancer CenterNew York, New York